Moderna
MRNA · NASDAQ · Biotech · United States
Financials at a glance
Source: SEC XBRLAnnual
Quarterly · last 8
Revenue (FY2025)
$1.9B
Net margin
-145.2%
ROE
-32.6%
Revenue CAGR (2y)
-46.7%
EPS (FY2025)
-7.26
Net profit (FY2025)
$-2.8B
Ask MarketChacha about MRNA
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Jul 20, 2026
No specific company catalyst or filing identified for the July 20 move; Moderna shares moved lower alongside broader market or sector weakness as noted in recent market summaries.
- Jul 16, 2026
Moderna shares tumbled with no clear company-specific catalyst identified, consistent with profit-taking in biotech names after recent gains and sector rotation.
source 1 ↗· confidence: low - Jul 10, 2026
Moderna shares fell sharply after JPMorgan reaffirmed its Sell rating and included the stock on a list of 25 names to short into Q3, citing that recent gains had already priced in pipeline success such as the Merck melanoma partnership.
source 1 ↗· confidence: high - Jul 9, 2026
Moderna shares rose on positive analyst actions including price target increases from Morgan Stanley, BofA, and RBC Capital, alongside news of a new board appointment (Michael McDonnell) disclosed in the July 8 8-K and a recent EU contract for up to 24 million RSV vaccine doses.
- Jul 8, 2026
Moderna shares fell as investors took profits following a sharp June rally that delivered nearly 50% gains, with momentum fading and no major negative catalyst reported.
source 1 ↗· confidence: medium - Jul 2, 2026
Moderna shares rose on positive pipeline updates and encouraging flu vaccine data that lifted sentiment, per multiple July 2 reports; the move continued momentum from recent FDA-related developments.
- Jul 1, 2026
Moderna shares rose on continued momentum from its late-June mRNA pipeline update and positive FDA advisory committee vote on the mRNA-1010 flu vaccine, with no new company-specific catalyst reported for July 1.
- Jun 29, 2026
Moderna shares continued their recent rally on ongoing investor optimism around its cancer pipeline, CAR-T efforts, and plans to expand the mRNA platform beyond vaccines into oncology and other areas, per multiple market reports.
- Jun 26, 2026
Moderna shares surged on optimism from its June 25 Science Day updates highlighting pipeline expansion into oncology and autoimmune diseases, including in vivo CAR-T (mRNA-6007) and T-cell engager programs, plus recent FDA advisory support for its flu vaccine.
- Jun 22, 2026
Moderna shares fell after snapping a six-day rally driven by recent positive FDA flu vaccine updates, amid broader market pressures weighing on biotech stocks and some valuation concerns.
- Jun 18, 2026
Moderna shares rose after an FDA advisory committee voted unanimously 9-0 in favor of its mRNA-1010 (mFlusiva) flu vaccine for older adults, ahead of an August 5, 2026 decision.
Daily moves with the verified reason behind them. Education only — not investment advice.
On MarketChacha
Posts about MRNA- Moderna Q2 results: what the numbers sayc/us-daily · 7/31/2026▲ 0
- Why did Moderna (MRNA) crash ~11% Friday? JPMorgan told clients to short itc/usmarkets · 7/12/2026▲ 0
- Moderna just filed an 8-K: what it meansc/us-daily · 7/8/2026▲ 1
- Why is Moderna (MRNA) up ~6% today while tech sinks?c/usmarkets · 6/23/2026▲ 0
Financials
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2025 | $1.9B | $-2.8B | -7.26 | -145.2% | -32.6% |
| FY2024 | $3.2B | $-3.6B | -9.28 | -110.0% | -32.7% |
| FY2023 | $6.8B | $-4.7B | -12.33 | -68.8% | -34.0% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin |
|---|---|---|---|---|
| 2026Q2 | $145.0M | $-782.0M | -1.97 | -539.3% |
| 2026Q1 | $389.0M | $-1.3B | -3.40 | -345.2% |
| 2025Q3 | $1.0B | $-200.0M | -0.51 | -19.7% |
| 2025Q2 | $142.0M | $-825.0M | -2.13 | -581.0% |
| 2025Q1 | $108.0M | $-971.0M | -2.52 | -899.1% |
| 2024Q3 | $1.9B | $13.0M | 0.03 | 0.7% |
| 2024Q2 | $241.0M | $-1.3B | -3.33 | -530.7% |
| 2024Q1 | $167.0M | $-1.2B | -3.07 | -703.6% |
| 2023Q3 | $1.8B | $-3.6B | -9.53 | -198.3% |
| 2023Q2 | $344.0M | $-1.4B | -3.62 | -401.2% |
| 2023Q1 | $1.9B | $79.0M | 0.19 | 4.2% |
Figures as reported, in reporting currency. Source: SEC XBRL.
Filings & announcements
2026
- SEC7/31/2026
- SEC7/31/2026material
- SEC7/8/2026material
- SEC5/11/2026material
- SEC5/1/2026material
- SEC5/1/2026
- SEC3/5/2026material
- SEC2/20/2026
- SEC2/13/2026material
- SEC2/11/2026material
- SEC1/12/2026material
- SEC1/5/2026material
2025
- SEC11/24/2025material
- SEC11/20/2025material
- SEC11/13/2025material
- SEC11/6/2025material
- SEC11/6/2025
- SEC8/1/2025material
- SEC8/1/2025
In the news
- Moderna Stock Falls 5% After Trimming Financial OutlookTIKR.com · 8/2/2026
- California State Teachers Retirement System Purchases 58,529 Shares of Moderna, Inc. $MRNAMarketBeat · 8/2/2026
- Moderna (MRNA) Stock Falls As Pipeline Delays Cloud Revenue Growthsimplywall.st · 8/2/2026
- Moderna (MRNA) Stock Looks Strong On Returns But Fully Priced On Salessimplywall.st · 8/1/2026
- Moderna Stock Has Doubled This Year. Can Earnings Keep the Rally Alive?Barron's · 7/31/2026
- Moderna, Inc. $MRNA Shares Sold by Bank of Nova ScotiaMarketBeat · 7/31/2026
- Baillie Gifford Reduces Moderna Inc (MRNA) Stake -- Shares Trade at 2.54x GF ValueGuruFocus · 7/31/2026
- Moderna’s Stock Continues Volatile Trading Into Earningsthebull.com.au · 7/30/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.